

*Chi-Huey Wong (Ed.)*

## **Carbohydrate-based Drug Discovery**



**WILEY-  
VCH**

WILEY-VCH GmbH & Co. KGaA



*Chi-Huey Wong (Ed.)*

**Carbohydrate-based Drug Discovery**

## ***Further Titles of Interest***

K. C. Nicolaou, R. Hanko, W. Hartwig (Eds.)

### **Handbook of Combinatorial Chemistry**

2002

ISBN 3-527-30509-2

M. Demeunynck, C. Bailly, W.D. Wilson (Eds.)

### **DNA and RNA Binders – From Small Molecules to Drugs**

2002

ISBN 3-527-30595-5

B. Ernst, G.W. Hart, P. Sinay (Eds.)

### **Carbohydrates in Chemistry and Biology**

2000

ISBN 3-527-29511-9

T. K. Lindhorst

### **Essentials of Carbohydrate Chemistry and Biochemistry (2nd Ed.)**

2002

ISBN 3-527-30664-1

N. Sewald, H.-D. Jakubke

### **Peptides: Chemistry and Biology**

2002

ISBN 3-527-30405-3

*Chi-Huey Wong (Ed.)*

## **Carbohydrate-based Drug Discovery**



**WILEY-  
VCH**

WILEY-VCH GmbH & Co. KGaA

**Prof. Dr. Chi-Huey Wong**  
Ernest W. Hahn Chair in Chemistry  
The Scripps Research Institute  
10550 N. Torrey Pines Road  
La Jolla, CA 92037  
USA  
wong@scripps.edu

■ This book was carefully produced. Nevertheless, authors, editor and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Bibliographic information published  
by Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>

© 2003 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**Typesetting** K+V Fotosatz GmbH, Beerfelden  
**Printing** Strauss Offsetdruck GmbH,  
Mörlenbach  
**Bookbinding** J. Schäffer GmbH & Co. KG,  
Grünstadt

**ISBN** 3-527-30632-3

## Contents

### Volume 1

Preface XXV

List of Contributors XXVII

<b>1</b>	<b>Synthetic Methodologies</b>	<b>1</b>
	<i>Chikako Saotome and Osamu Kanie</i>	
1.1	Introduction	1
1.2	Tactical Analysis for Overall Synthetic Efficiency	1
1.3	Methodological Improvements	2
1.3.1	Chemistry	3
1.3.2	Protecting Group Manipulations	4
1.3.3	Modulation of the Reactivity of Glycosyl Donors	6
1.3.4	Block Synthesis	8
1.4	Accessibility	11
1.4.1	Solution-based Chemistry	11
1.4.2	One-Pot Glycosylation	13
1.4.3	Solid-Phase Chemistry	16
1.4.3.1	Fundamentals of Solid-Phase Oligosaccharide Synthesis	16
1.4.3.2	The Support	16
1.4.3.3	Linkers to the Support	20
1.4.3.4	Protecting Groups used in Solid-Phase Oligosaccharide Synthesis	20
1.4.3.5	Solid-Phase Oligosaccharide Synthesis	20
1.4.3.6	Monitoring of Reaction Progress	26
1.4.4	Automation	29
1.5	Concluding Remarks	32
1.6	References	33
<b>2</b>	<b>Complex Carbohydrate Synthesis</b>	<b>37</b>
	<i>Makoto Kiso, Hideharu Ishida, and Hiromune Ando</i>	
2.1	Introduction	37
2.2	Synthetic Gangliosides	38
2.2.1	Gangliosides GM4 and GM3, and their Analogues and Derivatives	38

2.2.2	Sialylparagloboside (SPG) Analogues and Derivatives	40
2.2.3	Selectin Ligands	43
2.2.3.1	Sialyl Lewis x	44
2.2.3.2	Novel 6-Sulfo sLe <sup>x</sup> Variants	45
2.2.4	Siglec ligands	46
2.2.4.1	Chol-1 ( <i>α</i> -Series) Gangliosides	47
2.2.4.2	Novel Sulfated Gangliosides	50
2.3	Toxin Receptor	50
2.4	Summary and Perspectives	52
2.5	References	52
<b>3</b>	<b>The Chemistry of Sialic Acid</b>	<b>55</b>
	<i>Geert-Jan Boons and Alexei V. Demchenko</i>	
3.1	Introduction	55
3.2	Chemical and Enzymatic Synthesis of Sialic Acids	56
3.3	Chemical Glycosidation of Sialic Acids	59
3.3.1	Direct Chemical Sialylations	60
3.3.1.1	2-Chloro Derivatives as Glycosyl Donors	61
3.3.1.2	2-Thio Derivatives as Glycosyl Donors	62
3.3.1.3	2-Xanthates as Glycosyl Donors	69
3.3.1.3	2-Phosphites as Glycosyl Donors	71
3.3.1.4	Miscellaneous Direct Chemical Methods	71
3.3.2	Indirect Chemical Methods with the Use of a Participating Auxiliary at C-3	73
3.3.2.1	3-Bromo- and other 3-O-Auxiliaries	73
3.3.2.2	3-Thio and 3-Seleno Auxiliaries	74
3.3.3	Synthesis of (2→8)-Linked Sialosides	77
3.4	Enzymatic Glycosidations of Sialic Acids	83
3.4.1	Sialyltransferases	84
3.4.1.1	Metabolic Engineering of the Sialic Acid Biosynthetic Pathway	90
3.4.2	Sialidases	90
3.5	Synthesis of C- and S-Glycosides of Sialic Acid	91
3.6	Modifications at N-5	94
3.7	References	95
<b>4</b>	<b>Solid-Phase Oligosaccharide Synthesis</b>	<b>103</b>
	<i>Peter H. Seeberger</i>	
4.1	Introduction	103
4.2	Pioneering Efforts in Solid-Phase Oligosaccharide Synthesis	104
4.3	Synthetic Strategies	105
4.3.1	Immobilization of the Glycosyl Acceptor	106
4.3.2	Immobilization of the Glycosyl Donor	106
4.3.3	Bi-directional Strategy	107
4.4	Support Materials	107
4.4.1	Insoluble Supports	107

4.4.2	Soluble Supports	108
4.5	Linkers	108
4.5.1	Silyl Ethers	108
4.5.2	Acid- and Base-Labile Linkers	109
4.5.3	Thioglycoside Linkers	110
4.5.4	Linkers Cleaved by Oxidation	110
4.5.5	Photocleavable Linkers	111
4.5.6	Linkers Cleaved by Olefin Metathesis	111
4.6	Synthesis of Oligosaccharides on Solid Support by Use of Different Glycosylating Agents	112
4.6.1	1,2-Anhydrosugars – The Glycal Assembly Approach	112
4.6.2	Glycosyl Sulfoxides	113
4.6.3	Glycosyl Trichloroacetimidates	114
4.6.4	Thioglycosides	115
4.6.5	Glycosyl Fluorides	118
4.6.6	<i>n</i> -Pentenyl Glycosides	118
4.6.7	Glycosyl Phosphates	118
4.7	Automated Solid-Phase Oligosaccharide Synthesis	118
4.7.1	Fundamental Considerations	119
4.7.2	Automated Synthesis with Glycosyl Trichloroacetimidates	121
4.7.3	Automated Synthesis with Glycosyl Phosphates	121
4.7.4	Automated Oligosaccharide Synthesis by Use of Different Glycosylating Agents	121
4.7.5	“Cap-Tags” to Suppress Deletion Sequences	123
4.7.6	Current State of the Art of Automated Synthesis	123
4.8	Conclusion and Outlook	124
4.9	References	125
<b>5</b>	<b>Solution and Polymer-Supported Synthesis of Carbohydrates</b>	<b>129</b>
	<i>Shin-Ichiro Nishimura</i>	
5.1	Introduction	129
5.2	Mimicking Glycoprotein Biosynthetic Systems	130
5.3	References	136
<b>6</b>	<b>Enzymatic Synthesis of Oligosaccharides</b>	
	<i>Jianbo Zhang, Jun Shao, Prezemk Kowal, and Peng George Wang</i>	
6.1	Introduction	137
6.2	Sugar Nucleotide Biosynthetic Pathways	140
6.2.1	Basic Principle	140
6.2.2	Regeneration Systems for nine Common Sugar Nucleotides	142
6.2.2.1	Regeneration Systems for UDP-Gal, UDP-Glc, UDP-GlcA and UDP-Xyl	142
6.2.2.2	Regeneration Systems for UDP-GlcNAc and UDP-GalNAc	144
6.2.2.3	Regeneration Systems for GDP-Man and GDP-Fuc	147
6.2.2.4	CMP-Neu5Ac Regeneration	149

6.2.3	Novel Energy Source in Sugar Nucleotide Regeneration	150
6.3	Enzymatic Oligosaccharide Synthesis Processes	151
6.3.1	Cell-Free Oligosaccharide Synthesis	151
6.3.1.1	Immobilized Glycosyltransferases and Water-Soluble Glycopolymer	152
6.3.1.2	“Superbeads”	154
6.3.2	Large-Scale Syntheses of Oligosaccharides with Whole Cells	156
6.3.2.1	Kyowa Hakko’s Technology	157
6.3.2.2	Wang’s “Superbug”	157
6.3.2.3	Other Whole Cell-Based Technologies	161
6.4	Future Directions	162
6.5	References	162
<b>7</b>	<b>Glycopeptides and Glycoproteins: Synthetic Chemistry and Biology</b>	<b>169</b>
	<i>Oliver Seitz</i>	
7.1	Introduction	169
7.2	The Glycosidic Linkage	169
7.3	The Challenges of Glycopeptide Synthesis	171
7.4	Synthesis of Preformed Glycosyl Amino Acids	173
7.4.1	N-Glycosides	173
7.4.2	O-Glycosides	176
7.4.2.1	O-Glycosyl Amino Acids bearing Mono- or Disaccharides	176
7.4.2.2	O-Glycosyl Amino Acids bearing Complex Carbohydrates	179
7.5	Synthesis of Glycopeptides	181
7.5.1	N-Glycopeptide Synthesis in Solution	181
7.5.2	O-Glycopeptide Synthesis in Solution	185
7.5.3	Solid-Phase Synthesis of N-Glycopeptides	188
7.5.4	Solid-Phase Synthesis of O-Glycopeptides	192
7.6	Biological and Biophysical Studies	200
7.6.1	Conformations of Glycopeptides	200
7.6.2	Glycopeptides as Substrates of Enzymes and Receptors	203
7.6.3	Glycopeptides and Cancer Immunotherapy	204
7.6.4	Glycopeptides and T Cell Recognition	206
7.7	Summary and Outlook	208
7.8	References	209
<b>8</b>	<b>Synthesis of Complex Carbohydrates: Everninomicin 13,384-1</b>	<b>215</b>
	<i>K. C. Nicolaou, Helen J. Mitchell, and Scott A. Snyder</i>	
8.1	Introduction	215
8.2	Retrosynthetic Analysis and Strategy	218
8.2.1	Overview of Synthetic Strategies and Methodologies	218
8.2.2	Retrosynthetic Analysis: Overall Approach	222
8.3	Total Synthesis of Everninomicin 13,384-1 (1)	223
8.3.1	Approaches Towards the A <sub>1</sub> B(A)C Fragment	223
8.3.1.1	Initial Model Studies	223
8.3.1.2	Construction of the Building Blocks	225

8.3.1.3	Assembly and Completion of the A <sub>1</sub> B(A)C Fragment	229
8.3.2	Construction of the FGHA <sub>2</sub> Fragment	231
8.3.2.1	First Generation Approach to the FGHA <sub>2</sub> Fragment	231
8.3.2.2	Second Generation Strategy Towards the FGHA <sub>2</sub> Fragment	232
8.3.2.3	Assembly of the FGHA <sub>2</sub> Fragment	235
8.3.3	Construction of the DE Disaccharide	241
8.3.3.1	Retrosynthetic Analysis and Construction of Building Blocks for the DE Fragment	241
8.3.3.2	Assembly of the DE Fragment	243
8.3.3.3	Test of Strategies	244
8.3.4	Assembly of the DEFGHA <sub>2</sub> Fragment	245
8.3.5	Completion of the Total Synthesis of Everninomicin 13,384-1	247
8.4	Conclusion	249
8.5	References	250

## 9 Chemical Synthesis of Asparagine-Linked Glycoprotein Oligosaccharides: Recent Examples 253

*Yukishige Ito and Ichiro Matsuo*

9.1	Introduction	253
9.2	Synthesis of Asn-Linked Oligosaccharides: Basic Principles	257
9.3	Chemical Synthesis of Complex Oligosaccharides	261
9.3.1	Classical Examples	261
9.3.2	Trichloroacetimidate Approach to Complex-Type Glycan Chains	265
9.3.3	<i>n</i> -Pentenyl Glycosides as Glycosyl Donors	265
9.3.4	Glycal Approach to Complex Oligosaccharides	267
9.3.5	Intramolecular Aglycon Delivery Approach	269
9.3.6	New Protecting Group Strategy	273
9.3.7	Linear Synthesis of Branched Oligosaccharide	274
9.3.8	Chemoenzymatic Approach to Complex-type Glycans	275
9.4	References	278

## 10 Chemistry and Biochemistry of Asparagine-Linked Protein Glycosylation 281

*Barbara Imperiali and Vincent W.-F. Tai*

10.1	Protein Glycosylation	281
10.1.1	Introduction	281
10.1.2	Asparagine-Linked Glycosylation and Oligosaccharyl Transferase	281
10.2	Small-Molecule Probes of the Biochemistry of Oligosaccharyl Transferase	283
10.2.1	Photoaffinity and Affinity Labeling of Oligosaccharyl Transferase	284
10.2.2	Investigation of Peptide-Based Substrate Analogues as Inhibitors of Oligosaccharyl Transferase	287
10.2.2.1	Inhibitors of <i>N</i> -Linked Glycosylation and Glycoprotein Processing	287
10.2.2.2	Peptide-Based Analogues and Inhibitors	288
10.2.2.3	Interim Summary	292

10.2.3	Investigation of Carbohydrate-Based Substrate Analogues as Probes of Oligosaccharyl Transferase Function	292
10.2.3.1	Possible Mechanisms for Glycosyl Transfer	294
10.2.3.2	Probing of the Mechanism of Oligosaccharyl Transferase with Potential Inhibitors	296
10.2.3.3	Interim Summary	300
10.3	Conclusions	301
10.4	References	301
<b>11</b>	<b>Conformational Analysis of C-Glycosides and Related Compounds: Programming Conformational Profiles of C- and O-Glycosides</b>	<b>305</b>
	<i>Peter G. Goekjian, Alexander Wei, and Yoshito Kishi</i>	
11.1	Introduction	305
11.2	Stereoelectronic Effects and the <i>exo</i> -Anomeric Conformation	306
11.3	Conformational Analysis of C-Glycosides: C-Monoglycosides	309
11.4	1,4-Linked C-Disaccharides: the Importance of <i>syn</i> -Pentane Interactions	314
11.5	Prediction of Conformational Preference and Experimental Validation	318
11.6	Programming Oligosaccharide Conformation	322
11.7	Conformational Design of C-Trisaccharides based on a Human Blood Group Antigen	323
11.8	Conformational Design: Relationship to Biological Activity	330
11.8.1	C-Lactose vs. O-Lactose	331
11.8.2	Human Blood Group Trisaccharides	334
11.9	Concluding Remarks	336
11.10	Acknowledgements	337
11.11	References	337
<b>12</b>	<b>Synthetic Lipid A Antagonists for Sepsis Treatment</b>	<b>341</b>
	<i>William J. Christ, Lynn D. Hawkins, Michael D. Lewis, and Yoshito Kishi</i>	
12.1	Background	341
12.2	Hypothesis and Approach	342
12.2.1	Monosaccharide Antagonists: Lipid X Analogues	343
12.2.2	Disaccharide Antagonist of Lipid A: First Generation	344
12.2.3	Disaccharide Antagonist of Lipid A: Second Generation	348
12.3	Conclusion	351
12.4	Acknowledgement	353
12.5	References	353
<b>13</b>	<b>Polysialic Acid Vaccines</b>	<b>357</b>
	<i>Harold J. Jennings</i>	
13.1	Introduction	357
13.2	Group C Meningococcal Vaccines	358

13.2.1	Structure and Immunology of GCMP	358
13.2.2	Group C Conjugate Vaccines	360
13.3	Group B Meningococcal Vaccines	362
13.3.1	Structure of GBMP	362
13.3.2	Immunology of GBMP	362
13.3.3	B Polysaccharide-Protein Conjugates	363
13.3.4	Extended Helical Epitope of PSA	364
13.4	Chemically Modified Group B Meningococcal Vaccines	366
13.4.1	N-Propionylated PSA Conjugate Vaccine	366
13.4.2	Immunology of NPr PSA	368
13.4.3	Protective Epitope mimicked by NPr PSA	370
13.4.4	Safety Concerns	370
13.5	Cancer Vaccines	371
13.5.1	PSA on Human Cells	371
13.5.2	Potential of NPr PSA as a Cancer Vaccine	373
13.6	Acknowledgements	375
13.7	References	375
<b>14</b>	<b>Synthetic Carbohydrate-Based Vaccines</b>	<b>381</b>
	<i>Stacy J. Keding and Samuel J. Danishefsky</i>	
14.1	Introduction	381
14.2	Cancer Vaccines	382
14.2.1	Carrier Proteins	384
14.2.2	Lipid Carriers	392
14.2.3	T-Cell Epitopes	394
14.2.4	Dendrimers	396
14.3	Bacterial Polysaccharide Vaccines	397
14.4	Synthetic Parasitic Polysaccharide Conjugate Vaccine	402
14.5	Conclusions	403
14.6	References	403
<b>15</b>	<b>Chemistry, Biochemistry, and Pharmaceutical Potentials of Glycosaminoglycans and Related Saccharides</b>	<b>407</b>
	<i>Tasneem Islam and Robert J. Linhardt</i>	
15.1	Introduction	407
15.1.1	Biological Activities	408
15.1.2	Heparin and Heparan Sulfate	409
15.1.2.1	Structure and Properties	409
15.1.2.2	Biosynthesis and Biological Functions	410
15.1.2.3	Applications of Heparin and Heparan Sulfate	411
15.2	Dermatan and Chondroitin Sulfates	417
15.2.1	Structure and Biological Role	417
15.2.2	Therapeutic Applications	418
15.2.2.1	Dermatan Sulfate	418

15.2.2.2	Chondroitin Sulfates	419
15.3	Hyaluronan	419
15.3.1	Structure and Properties	419
15.3.2	Tissue Distribution and Biosynthesis	420
15.3.3	Functions and Applications	421
15.3.3.1	Medical Applications	422
15.3.3.2	Hyaluronic Acid Biomaterials	423
15.4	Keratan Sulfate	423
15.4.1	Structure and Distribution	423
15.4.2	Chemistry and Biosynthesis of Linkage Regions	424
15.4.2.1	Keratan Sulfate on Cartilage Proteoglycans	424
15.4.2.2	Keratan Sulfate on Corneal Proteoglycans	424
15.4.3	Biological Roles of Keratan Sulfate	425
15.4.3.1	Role of KS in Macular Corneal Dystrophy	425
15.5	Other Acidic Polysaccharides	425
15.5.1	Acharan Sulfate	425
15.5.2	Fucoidins	426
15.5.3	Carrageenans	427
15.5.4	Sulfated Chitins	427
15.5.5	Dextran Sulfate	427
15.5.6	Alginates	428
15.5.7	Fully Synthetic Sulfated Molecules	428
15.5.7.1	Polymers	428
15.5.7.2	Small Sulfonated Molecules	428
15.6	Pharmaceutical Potential and Challenges	430
15.6.1	GAG-Based Agents Are Heterogenous	431
15.6.2	GAG-Based Agents and Sulfonated Analogues Have Low Bioavailability	431
15.6.3	GAGs Have a Myriad of Biological Activities	432
15.6.4	Carbohydrate-Based Drugs Are Expensive and Difficult to Prepare	432
15.7	Conclusion	432
15.8	References	433
<b>16</b>	<b>A New Generation of Antithrombotics Based on Synthetic Oligosaccharides</b>	<b>441</b>
	<i>Maurice Petitou and Jean-Marc Herbert</i>	
16.1	Introduction	441
16.2	Heparin and Its Mechanism of Action as an Antithrombotic Agent	442
16.2.1	Heparin, a Complex Polysaccharide with Blood Anticoagulant Properties	442
16.2.2	Which Coagulation Factor must be Inhibited?	442
16.2.3	The Structure of Heparin in Relation to Antithrombin Activation	444
16.2.4	The Limitations of Heparin	445
16.3	Synthetic Pentasaccharides, Selective Factor Xa Inhibitors, are Antithrombotic Agents	446

- 16.3.1 New Synthetic Oligosaccharides Required in Order to Validate A Pharmacological Hypothesis 446
- 16.3.2 A Strategy for the Synthesis of an Active Pentasaccharide 446
- 16.3.3 A Strategy for the Synthesis of the First Pentasaccharide 448
- 16.3.4 Activation of Antithrombin: Structure/Activity Relationship 449
- 16.3.5 Clinical Trials Results 449
- 16.3.6 The Second Generation of Antithrombotic Pentasaccharides 451
- 16.4 Synthetic Thrombin-Inhibiting Oligosaccharides: The Next Generation? 452
  - 16.4.1 First Approach: Oligomerization of a Disaccharide 452
  - 16.4.2 Second Approach: Molecules Containing Two Identified Domains 453
  - 16.4.3 Introduction of a Neutral Domain 454
- 16.5 The Mechanism of Antithrombin Activation by Synthetic Oligosaccharides 456
- 16.6 Conclusion and Perspectives 456
- 16.7 References 457

## Volume 2

- 17 Sequencing of Oligosaccharides and Glycoproteins 461**  
*Stuart M. Haslam, Kay-Hooi Khoo, and Anne Dell*
  - 17.1 Mass Spectrometry 462
    - 17.1.1 EI-, FAB-, and MALDI-MS 462
    - 17.1.2 ES, NanoES, and LC-MS 464
    - 17.1.3 MS/MS and Mass Analyzers 465
  - 17.2 MS-Based Sequencing Strategies 466
    - 17.2.1 Chemical Derivatization 467
    - 17.2.2 MS/MS Fragmentation Patterns 467
    - 17.2.3 Permethylation and Sequence Assignment from Fragment Ions 468
  - 17.3 Glycan Sequencing and Structural Determination – A Case Study 470
    - 17.3.1 GC-MS Sugar Analysis 471
    - 17.3.2 Glycan Derivatization 471
    - 17.3.3 FAB-MS of the Deuteroreduced Permethyated HSP Sample 473
    - 17.3.4 ES-MS/MS 473
    - 17.3.5 Linkage Analysis 474
    - 17.3.6 Chemical Hydrolysis 474
    - 17.3.7 Exo-Glycosidase Digestion 474
  - 17.4 Mammalian Glycomics 475
  - 17.5 Some Special Case Strategies 477
  - 17.6 References 481

<b>18</b>	<b>Preparation of Heterocyclic 2-Deoxystreptamine Aminoglycoside Analogues and Characterization of their Interaction with RNAs by Use of Electrospray Ionization Mass Spectrometry</b> 483
	<i>Richard H. Griffey, Steven A. Hofstadler, and Eric E. Swayze</i>
18.1	Introduction 483
18.1.1	RNA as a Target 483
18.1.2	Functional RNA Subdomains 483
18.1.3	Aminoglycosides are a Privileged Class of RNA Ligands 484
18.2	ESI-MS for Characterization of Aminoglycoside-RNA Interactions 484
18.2.1	Aminoglycoside-16S and 18S A Site RNA Models 484
18.2.2	Neomycin and TAR RNA 489
18.2.3	Interim Summary 490
18.3	Preparation of Heterocyclic 2-Deoxystreptamines and Binding to a 16S A Site RNA Model 490
18.3.1	4-Substituted 2-Deoxystreptamine Derivatives 491
18.3.2	16S rRNA Binding Affinity Study in an ESI-MS Assay 493
18.3.3	Isolation of Sugar Ring Fragments from Neomycin 494
18.4	Preparation, Binding, and Biological Activity of Substituted Paromomycin Derivatives 495
18.4.1	Synthesis of Racemic A Ring-Substituted Paromomycin Analogues 495
18.4.2	Synthesis of Chiral A Ring-Substituted Paromomycin Analogues 496
18.5	Future Prospects 498
18.6	Acknowledgements 498
18.7	References 498
<b>19</b>	<b>Glycosylation Analysis of a Recombinant P-Selectin Antagonist by High-pH Anion-Exchange Chromatography with Pulsed Electrochemical Detection (HPAEC/PED)</b> 501
	<i>Mark R. Hardy and Richard J. Cornell</i>
19.1	Introduction 501
19.2	Use of HPAEC/PED in the Development of Biopharmaceuticals 502
19.3	Biology of P-Selectin 503
19.3.1	Structures of PSGL-1 and rPSGL-Ig 503
19.4	HPAEC/PED as an Adjunct to rPSGL-Ig Process Development 504
19.4.1	Materials and Methods 504
19.4.2	HPAEC/PED O-Linked Oligosaccharide Profile Analysis 506
19.4.3	N-Linked Oligosaccharide Profile Analysis 507
19.5	Results and Discussion 508
19.5.1	HPAEC/PED Oligosaccharide Profile Analysis of a Developmental Batch of rPSGL-Ig 508
19.5.2	Repeatability of the O-Linked Oligosaccharide Profile Method 510
19.5.3	O-Glycosylation of rPSGL-Ig Expressed by Different Cell Lines 510
19.5.4	N-Glycosylation of rPSGL-Ig 515

19.6	Summary	515
19.7	Acknowledgements	516
19.8	References	516
<b>20</b>	<b>Analytical Techniques for the Characterization and Sequencing of Glycosaminoglycans</b>	<b>517</b>
	<i>Ram Sasisekharan, Zachary Shriver, Mallik Sundaram, and Ganesh Venkataraman</i>	
20.1	Introduction to GAG Linear Complex Polysaccharides	517
20.2	Depolymerization of Nascent GAG Chains	521
20.2.1	Enzymes that Degrade GAGs	521
20.2.2	Chemical Methods for Degrading GAG Oligosaccharides	524
20.3	Detection of GAG Oligosaccharides	525
20.3.1	$\Delta^{4,5}$ Bond Formation and UV Detection	525
20.3.2	Fluorescent Tagging	526
20.3.3	Metabolic Labeling	526
20.4	Analytical Tools Used in the Structural Characterization of GAGs	527
20.4.1	High Pressure Liquid Chromatography	527
20.4.1.1	Amino-Bonded Silica	528
20.4.1.2	High-Performance Gel Permeation	528
20.4.1.3	Weak and Strong Anion Exchange	528
20.4.1.4	Pellicular Anion Exchange	529
20.4.1.5	IP-RPHPLC	529
20.4.1.6	Sequencing GAGs I: HPLC Methods	529
20.4.2	Polyacrylamide Gel Electrophoresis	530
20.4.2.1	Sequencing GAGs II: PAGE Methods	530
20.4.3	Capillary Electrophoresis	530
20.4.4	NMR Spectroscopy	532
20.4.5	Mass Spectrometry	533
20.4.5.1	Sequencing GAGs III: Mass Spectrometric Methodologies	536
20.4.6	Oligosaccharide Array Technologies	536
20.5	Future Directions	536
20.6	Acknowledgements	537
20.7	References	537
<b>21</b>	<b>Thermodynamic Models of the Multivalency Effect</b>	<b>541</b>
	<i>Pavel I. Kitov and David R. Bundle</i>	
21.1	Introduction	541
21.2	Concept of Distribution Free Energy	542
21.2.1	Binding Isotherm	542
21.2.2	Competitive Inhibition Isotherm	544
21.3	Multivalent Receptor vs. Monovalent Ligand	546
21.3.1	Interim Summary	549
21.4	Multivalent Receptor vs. Multivalent Ligand	551
21.5	Topological Classification of Multivalent Systems	553

21.5.1	Indifferent Presentation	553
21.5.2	Linear Presentation	554
21.5.3	Circular Presentation	554
21.5.4	Radial Presentation	554
21.6	Determination of Microscopic Binding Parameters by Molecular Modeling	555
21.6.1	Optimization of the Tether in Bivalent P <sup>k</sup> -Trisaccharide Ligands for Shiga-Like Toxin	557
21.7	Determination of Microscopic Binding Parameters from Binding Data	561
21.8	Thermodynamic Analysis of Multivalent Interaction	562
21.8.1	Radially Arranged Multivalent Ligands for Shiga-Like Toxin	565
21.9	Conclusions	570
21.10	Mathematical Appendix	570
21.10.1	Calculation of Statistical Coefficients	570
21.10.2	Multivalent Receptor and Monovalent Ligand	571
21.10.3	Multivalent Binding with Linear and Circular Topology	571
21.10.4	Multivalent Binding with Radial Topology	572
21.10.5	Derivation of Eq. (24)	572
21.11	References	573
<b>22</b>	<b>Synthetic Multivalent Carbohydrate Ligands as Effectors or Inhibitors of Biological Processes</b>	<b>575</b>
	<i>Laura L. Kiessling, Jason K. Pontrello, and Michael C. Schuster</i>	
22.1	Introduction	575
22.1.1	Mechanisms of Binding of Multivalent Ligands	576
22.1.2	Investigating the Structure/Function Relationship of a Series of Ligand Classes	577
22.2	Multivalent Carbohydrate Ligands as Inhibitors	581
22.2.1	Multivalency with AB <sub>5</sub> Toxins	581
22.2.1.1	Bundle's Decavalent Ligand for the <i>E. coli</i> Shiga-Like Toxin	582
22.2.1.2	Fan's Pentavalent Ligands for Cholera Toxin and the <i>E. coli</i> Heat-Labile Enterotoxin	584
22.2.2	Multivalency in Anti-adhesives	587
22.2.2.1	Low Molecular Weight Multivalent Carbohydrate Inhibitors of Bacterial Adhesion	587
22.2.2.2	Polymeric Multivalent Carbohydrate Inhibitors of Influenza Virus	592
22.2.3	Multivalent Carbohydrate Ligands as Inhibitors of Immune Responses	595
22.3	Multivalent Carbohydrate Ligands as Effectors	596
22.3.1	Low Molecular Weight Multivalent Effectors	597
22.3.2	Multivalency in Targeting Strategies	599
22.3.3	Multivalent Bacterial Chemoattractants	600
22.3.4	Multivalent Ligand-Mediated Cell Aggregation	602
22.3.5	Multivalent Ligands and the Selectins	603

- 22.4 Conclusions 605
- 22.5 References 605
  
- 23 Glycosyltransferase Inhibitors 609**  
*Karl-Heinz Jung and Richard R. Schmidt*
- 23.1 Introduction 609
- 23.2 Glycosyltransferases Utilizing NDP-Sugar Donors 610
  - 23.2.1 Inverting Glycosyltransferases 610
    - 23.2.1.1  $\beta$ -Glucosyltransferases 611
    - 23.2.1.2  $\beta$ -Galactosyltransferases 616
    - 23.2.1.3  $\beta$ -N-Acetylglucosaminyltransferases 620
    - 23.2.1.4  $\alpha$ -Fucosyltransferases 625
    - 23.2.1.5  $\beta$ -Glucuronosyltransferases 632
  - 23.2.2 Retaining Glycosyltransferases 636
    - 23.2.2.1  $\alpha$ -Galactosyltransferases 637
    - 23.2.2.2  $\alpha$ -N-Acetylgalactosaminyltransferases 640
- 23.3 Glycosyltransferases Utilizing NMP-Sugar Donors 641
  - 23.3.1  $\alpha$ (2–6)Sialyltransferases 641
  - 23.3.2  $\alpha$ (2–3)Sialyltransferases and  $\alpha$ (2–8)Sialyltransferases 647
- 23.4 Bisubstrate Analogues as Inhibitors 648
- 23.5 Conclusion 653
- 23.6 References 654
  
- 24 RNA-Aminoglycoside Interactions 661**  
*Haim Weizman and Yitzhak Tor*
- 24.1 RNA as an Emerging Therapeutic Target 661
- 24.2 Aminoglycoside Antibiotics: Past and Present 664
- 24.3 Aminoglycosides as RNA Binders 666
- 24.4 Identifying RNA Targets and Developing Binding Assays 670
- 24.5 Dimeric Aminoglycosides 673
- 24.6 Aminoglycoside-Intercalator Conjugates 675
- 24.7 Guanidinoglycosides 677
- 24.8 Summary and Outlook 679
- 24.9 Acknowledgements 680
- 24.10 References 680
  
- 25 Glycosylated Natural Products 685**  
*Jon S. Thorson and Thomas Vogt*
- 25.1 Introduction 685
- 25.2 A Summary of Bioactive Glycosylated Secondary Metabolites 686
  - 25.2.1 Agents that Interact with DNA 686
    - 25.2.1.1 Eneidyne 686
    - 25.2.1.2 Bleomycins 688
    - 25.2.1.3 Diazobenzofluorenes 689
    - 25.2.1.4 Anthracyclines 689

25.2.1.5	Pluramycins	689
25.2.1.6	Aureolic Acids	690
25.2.2	Agents that Interact with RNA	692
25.2.2.1	Orthosomycins	692
25.2.2.2	Macrolides	692
25.2.2.3	Aminoglycosides	694
25.2.2.4	Amicetins	695
25.2.3	Agents that Interact with Cell Walls and Cell Membranes	695
25.2.3.1	Non-Ribosomal Peptides	695
25.2.3.2	Polyenes	697
25.2.3.3	Saccharomicins	699
25.2.4	Agents that Interact with Proteins	699
25.2.4.1	Indolocarbazoles	699
25.2.4.2	Coumarins	699
25.2.4.3	Benzoisochromanequinones	701
25.2.4.4	Avermectins	701
25.2.4.5	Angucyclines	701
25.2.4.6	Cardiac Glycosides	702
25.2.4.7	Lignans	703
25.2.4.8	Anthraquinone Glycosides	703
25.2.4.9	Ginsenosides	704
25.2.4.10	Glycoalkaloids	704
25.2.4.11	Glucosinolates	705
25.2.5	Agents that Interact with Other (or Undefined) Targets	706
25.2.5.1	Plant Phenolics	706
25.2.5.2	Mono- and Triterpenoid Glycosides	707
25.2.5.3	Plant Polymeric Natural Glycosides	707
25.3	Conclusions	707
25.4	References	707
<b>26</b>	<b>Novel Enzymatic Mechanisms in the Biosynthesis of Unusual Sugars</b>	<b>713</b>
	<i>Alexander Wong, Xuemei He, and Hung-Wen Liu</i>	
26.1	Introduction	713
26.2	Biosynthesis of Deoxysugars	714
26.2.1	$E_{od}$ -Catalyzed C-O Bond-Cleavage at the C-6 Position in the Biosynthesis of 6-Deoxyhexose	715
26.2.1.1	Catalytic Mechanism of $E_{od}$	715
26.2.1.2	Stereochemical Course of $E_{od}$ -Catalyzed Reactions	716
26.2.2	$E_1$ - and $E_3$ -Catalyzed C-O Bond-Cleavage at the C-3 Position in the Biosynthesis of Ascarylose	717
26.2.2.1	Catalytic Properties of CDP-6-Deoxy-L-Threo-D-Glycero-4-Hexulose 3-Dehydrase ( $E_1$ )	718
26.2.2.2	Catalytic Properties of CDP-6-Deoxy-L-Threo-D-Glycero-4-Hexulose 3-Dehydrase Reductase ( $E_3$ )	719
26.2.2.3	Formation of Radical Intermediates During $E_1$ and $E_3$ Catalysis	719

- 26.2.3 TylX3- and TylC1-Catalyzed C-O Bond-Cleavage at the C-2 Position in the Biosynthesis of Mycarose 720
  - 26.2.3.1 Biochemical Characterization of Enzymes Involved in C-2 Deoxygenation 721
  - 26.2.3.2 Mechanism of C-2 Deoxygenation 721
- 26.2.4 *DesI*- and *DesII*-Catalyzed C-O Bond-Cleavage at the C-4 Position in the Biosynthesis of Desosamine 722
  - 26.2.4.1 Genetic Disruption of *DesI* and *DesII* Genes 723
  - 26.2.4.2 Proposed Mechanisms for C-4 Deoxygenation 723
- 26.3 Biosynthesis of Aminosugars 725
  - 26.3.1 C-N Bond-Formation by GlmS-Catalyzed Transamidation in the Biosynthesis of Glucosamine-6-Phosphate 727
    - 26.3.1.1 Catalytic Properties of Glucosamine-6-Phosphate Synthetase 727
    - 26.3.1.2 The Glutaminase Activity of Glucosamine-6-Phosphate Synthetase 727
    - 26.3.1.3 The Synthetase Activity of Glucosamine-6-Phosphate Synthetase 728
  - 26.3.2 C-N Bond Formation by TylB-Catalyzed Transamination in the Biosynthesis of Mycaminose 729
- 26.4 Biosynthesis of Branched-Chain Sugars 730
  - 26.4.1 YerE- and YerF-Catalyzed Two-Carbon Branched-Chain Attachment in the Biosynthesis of Yersiniose A 731
    - 26.4.1.1 Biochemical Properties and Catalytic Mechanism of YerE 731
    - 26.4.1.2 Biochemical Properties of YerF 732
  - 26.4.2 TylC3-Catalyzed One-Carbon Branched-Chain Attachment in the Biosynthesis of Mycarose 732
    - 26.4.2.1 Biochemical Properties and Catalytic Mechanism of TylC3 733
- 26.5 Epimerization Reactions 734
  - 26.5.1 UDP-*N*-acetylglucosamine 2-Epimerase-Catalyzed C-2 Epimerization in the Biosynthesis of *N*-Acetylmannosamine 734
    - 26.5.1.1 Catalytic Properties of UDP-*N*-Acetylglucosamine 2-Epimerase 734
    - 26.5.1.2 Mechanism of C-2 Epimerization 735
  - 26.5.2 CDP-Tyvelose 2-Epimerase-Catalyzed C-2 Epimerization in the Biosynthesis of Tyvelose 735
    - 26.5.2.1 Biochemical Properties of CDP-Tyvelose 2-Epimerase 736
    - 26.5.2.2 Possible Mechanisms for C-2 Epimerization 737
    - 26.5.2.3 Distinguishing Between Mechanisms Involving C-2 or C-4 Oxidation 737
- 26.6 Rearrangement of Hexose Skeletons: UDP-Galactopyranose Mutase-Catalyzed Biosynthesis of Galactofuranose 738
  - 26.6.1 Catalytic Properties of UDP-Galactopyranose Mutase 738
  - 26.6.2 Mechanism of Ring Contraction 739
- 26.7 Summary 740

26.8	Acknowledgements	741
26.9	References	741
<b>27</b>	<b>Neoglycolipids: Identification of Functional Carbohydrate Epitopes</b>	<b>747</b>
	<i>Ten Feizi, Alexander M. Lawson, and Wengang Chai</i>	
27.1	Rationale for Developing Neoglycolipids as Oligosaccharide Probes	747
27.2	The First and Second Generation Neoglycolipids	749
27.3	Mass Spectrometry of Neoglycolipids	750
27.4	Scope of the Neoglycolipid Technology	752
27.4.1	Novel Sulfated Ligands for the Selectins	752
27.4.2	Novel Class of O-Glycans (O-Mannosyl) in the Brain	754
27.4.3	Unique Tetrasaccharide Sequence on Heparan Sulfate	755
27.5	Oligosaccharide Microarrays	755
27.6	Summary and Perspectives	757
27.7	Acknowledgement	757
27.8	References	757
<b>28</b>	<b>A Preamble to Aglycone Reconstruction for Membrane-Presented Glycolipid Mimics</b>	<b>761</b>
	<i>Murugesapillai Mylvaganam and Clifford A. Lingwood</i>	
28.1	Introduction	761
28.2	The Role of Ceramide Subtype Composition	762
28.3	Effects of Ceramide Subtype Composition in the Binding of Gb <sub>3</sub> Cer to Verotoxins	764
28.4	Hypothesis Regarding Lipid Replacement Structural Motifs (LRSMs)	766
28.5	Effect of Replacement of GSL Fatty Acyl Chains with Rigid, Non-Planar Hydrophobic Groups	768
28.6	Ada-Gb <sub>3</sub> Cer, a Functional Mimic of Membrane Presented Gb <sub>3</sub> Cer for VT Binding	769
28.7	Ceramide Subtype-Dependent Binding of Heat Shock Protein Hsp70 to Sulfogalactosyl Ceramide	772
28.8	Adamantyl-Acyl Ceramide is a Functional Replacement for a Ceramide-Cholesterol Composition: A Study with HIV Coat Protein gp120	775
28.9	Acknowledgement	777
28.10	References	777
<b>29</b>	<b>Small Molecule Inhibitors of the Sulfotransferases</b>	<b>781</b>
	<i>Dawn E. Verdugo, Lars C. Pedersen, and Carolyn R. Bertozzi</i>	
29.1	Introduction: Sulfotransferases and the Biology of Sulfation	781
29.2	EST as a Model ST for Inhibitor Design	783
29.2.1	Inhibitors of EST Targeted Toward the PAPS Binding Site	784
29.2.2	A Bisubstrate Analogue Approach to EST Inhibition	788
29.2.3	Discovery of EST Inhibitors from a Library of PAP Analogues	789

- 29.2.4 Inhibition of EST by Dietary Agents and Environmental Toxins 791
- 29.3 Inhibition of Representative Golgi-Resident Sulfotransferases: GST-2, GST-3, and TPST-2 792
  - 29.3.1 Heterocyclic Inhibitors of GST-2 and GST-3 792
  - 29.3.2 Tethered Inhibitors of TPST-2 793
- 29.4 Assays for High-Throughput Screening of STs 794
  - 29.4.1 A Continuous ST Assay 794
  - 29.4.2 Immobilized Enzyme Mass Spectrometry (IEMS) Assay 795
  - 29.4.3 A 96-Well Direct Capture 'Dot-Blot' Assay for Carbohydrate STs 795
- 29.5 New Directions in Inhibitor Discovery 796
- 29.6 Conclusions 796
- 29.7 Acknowledgements 796
- 29.8 References 797
  
- 30 Carbohydrate-Based Treatment of Cancer Metastasis 803**  
*Reiji Kannagi*
  - 30.1 Implication of Carbohydrate Determinants in Cancer Metastasis 803
    - 30.1.1 Distant Hematogenous Metastasis of Cancer Cells 803
    - 30.1.2 Multiple Organ Infiltration of Leukemic Cells 806
    - 30.1.3 Lymph Node Infiltration Mediated by L-Selectin 807
    - 30.1.4 Other Carbohydrate Determinants Involved in Distant Metastasis 807
  - 30.2 Tumor Angiogenesis and Cancer-Endothelial Interaction 808
    - 30.2.1 Possible Involvement of Selectin-Mediated Cell Adhesion in Tumor Angiogenesis 808
    - 30.2.2 Roles of Humoral Factors and Cell Adhesion Molecules in Tumor Angiogenesis 809
  - 30.3 Use of Monoclonal Antibodies for Inhibition of Cancer Cell-Endothelial Interaction 809
    - 30.3.1 Diversity of Selectin Ligand Expression on Cancer Cells 809
    - 30.3.2 Internally Fucosylated Ligands for Selectins 810
    - 30.3.3 Sulfated Ligands for Selectins 811
    - 30.3.4 O-Acetylation and Other Sialic Acid Modifications in Carbohydrate Ligands 812
  - 30.4 Inhibitors of Selectin-Mediated Cell Adhesion 812
    - 30.4.1 Use of Carbohydrate Derivatives 812
    - 30.4.2 Use of Peptide Mimetics 813
  - 30.5 Regulation of Selectin Expression on Endothelial Cells 814
    - 30.5.1 Enhanced E-Selectin Expression on Vascular Beds in Cancer Patients 814
    - 30.5.2 Factors Affecting Endothelial E-Selectin Expression in Patients with Cancers 815
    - 30.5.3 Chemoprophylaxis of Cancer Metastasis 815
  - 30.6 Enhanced Expression of Sialyl Le<sup>x</sup> and Sialyl Le<sup>a</sup> in Malignant Cells and its Modulation 816

- 30.6.1 Fucosyltransferases Involved in Sialyl Le<sup>a</sup> and Sialyl Le<sup>x</sup> Synthesis and Antisense Gene Therapy 816
- 30.6.2 Therapy Targeting Transcriptional Regulation of Fucosyltransferases VII and IV in Cancer and Leukemia 817
- 30.6.3 Cancer-Associated Alteration of Sialyltransferase Isoenzymes 818
- 30.6.4 Sialyltransferase and the Concept of Cancer-Associated “Incomplete Synthesis” of Carbohydrate Determinants 820
- 30.6.5 Sulfotransferase and Differentiation Therapy of Cancer with Histone Deacetylase Inhibitors 820
- 30.6.6 Effect of Sialidases and Membrane Recycling on Sialyl Le<sup>x/a</sup> Expression in Cancer 822
- 30.6.7 Substrate Competition with A- and B-Transferases and DNA Methylation 822
- 30.6.8 Altered Carbohydrate Intermediate Metabolism and Sialyl Le<sup>x/a</sup> Expression in Cancer – Possible Relation to Warburg Theory 823
- 30.7 References 824

## **31 N-Acetylneuraminic Acid Derivatives and Mimetics as Anti-Influenza Agents 831**

*Robin Thomson and Mark von Itzstein*

- 31.1 Introduction 831
  - 31.1.1 Influenza, the Disease 831
  - 31.1.2 The Virus 832
  - 31.1.3 Influenza Virus Sialidase 834
- 31.2 Structure-Based Design of Inhibitors of Influenza Virus Sialidase 836
- 31.3 Structure/Activity Relationship Studies of N-Acetylneuraminic Acid-Based Influenza Virus Sialidase Inhibitors 840
  - 31.3.1 C-4 Modifications 840
  - 31.3.2 C-5 Modifications 842
  - 31.3.3 C-6 Modifications 843
  - 31.3.4 Glycerol Side Chain Modifications 845
  - 31.3.5 Glycerol Side Chain Replacement 850
- 31.4 Concluding Remarks 856
- 31.5 Acknowledgements 856
- 31.6 References 857

## **32 Modified and Modifying Sugars as a New Tool for the Development of Therapeutic Agents – The Biochemically Engineered N-Acyl Side Chain of Sialic Acid: Biological Implications and Possible Uses in Medicine 863**

*Rüdiger Horstkorte, Oliver T. Keppler, and Werner Reutter*

- 32.1 Introduction 863
- 32.2 N-Acyl Side Chain-Modified Precursors of Sialic Acid 865

- 32.2.1 Biosynthetic Engineering of Cell Surface Sialic Acid as a Potent Tool for Study of Virus-Receptor Interactions 865
- 32.2.2 Immunotargeting of Tumor Cells Expressing Unnatural Polysialic Acids 868
- 32.2.3 Activation of Human T-Lymphocytes by ManProp 869
- 32.2.4 N-Acyl-Modified Sialic Acids can Stimulate Neural Cells 869
  - 32.2.4.1 Stimulation of Glial Cells 869
  - 32.2.4.2 Stimulation of Neurons 870
- 32.3 Outlook 871
- 32.4 Acknowledgements 872
- 32.5 Abbreviations 872
- 32.6 References 872
  
- 33 Modified and Modifying Sugars as a New Tool for the Development of Therapeutic Agents – Glycosidated Phospholipids as a New Type of Antiproliferative Agents 875**  
*Kerstin Danker, Annette Fischer, and Werner Reutter*
  - 33.1 Introduction 875
  - 33.2 Structures of Synthetic Glycosidated Phospholipid Analogues 876
  - 33.3 Antiproliferative Effect and Cytotoxicity of Glycosidated Phospholipid Analogues in Cell Culture Systems 876
  - 33.4 Effect of Glycosidated Phospholipid Analogues on Cell Matrix Adhesion 878
  - 33.5 Mechanisms of Action 879
  - 33.6 Outlook and New Developments 880
  - 33.7 Acknowledgements 881
  - 33.8 References 881
  
- 34 Glycoside Primers and Inhibitors of Glycosylation 883**  
*Jillian R. Brown, Mark M. Fuster, and Jeffrey D. Esko*
  - 34.1 Introduction 883
  - 34.2 Glycoside-Based Substrates 883
  - 34.3 Glycoside Primers – Xylosides 884
  - 34.4 Other Types of Primers 885
  - 34.5 Glycosides as Metabolic Decoys 888
  - 34.6 Analogues 890
  - 34.7 References 892
  
- 35 Carbohydrate-Based Drug Discovery in the Battle Against Bacterial Infections: New Opportunities Arising from Programmable One-Pot Oligosaccharide Synthesis 899**  
*Thomas K. Ritter and Chi-Huey Wong*
  - 35.1 Introduction 899
  - 35.2 Cell-Surface Carbohydrates 900
  - 35.3 Peptidoglycan 904

XXIV | Contents

35.4	Macrolide Antibiotics	913
35.5	Aminoglycosides	917
35.6	Programmable One-Pot Oligosaccharide Synthesis	922
35.7	Summary	927
35.8	References	928

<b>Subject Index</b>	933
----------------------	-----

- IV<sup>3</sup>NeuAca, III<sup>3</sup>FucanLc<sup>4</sup>Cer 133  
 (NeuNPSA)<sub>4</sub>-TT 368  
 neurons, stimulation of 870–871  
 nikkomycin Z 625  
 NIS/TfOH 63  
 nitrous acid 524  
 NK cells 806  
 NMP-sugar donors 641–648  
 NMR spectroscopy 23, 327, 532–533  
 – 2D-NOESY 327  
 – gated decoupling <sup>13</sup>C NMR 23  
 NodH 786  
 NOESY studies 316  
 – 2D-NOESY NMR spectroscopy 327  
*nonexo/gauche* conformation 307  
 non-lelior glycosyltransferase 138  
 non-ribosomal peptide 695–697  
 NPr PSA 370, 373  
 nucleotidyl-diphospho-4-hexulose 714
- o**
- OCH<sub>2</sub>CONMe<sub>2</sub> (*N,N*-dimethylglycolamido)  
 67  
 O-glycosides 305–337  
 oleandomycin 694  
 olefin metathesis, linkers cleaved by  
 111–112  
 oligosaccharide synthesis 1–3, 103–125  
 – arrays / microarrays 755–757  
 – asparagine-linked glycoprotein oligosac-  
 charides, chemical synthesis 253–278  
 – C-oligosaccharide 336  
 – enzymatic synthesis 137–162  
 – – cell-free 151–156  
 – – large-scale synthesis with whole cells  
 156–161  
 – – whole cell-based technologies 161  
 – *α*-Gal oligosaccharides 158  
 – *N*-linked oligosaccharide 507–508, 515  
 – *O*-linked oligosaccharide 511  
 – programmable 31  
 – – one-pot oligosaccharide synthesis  
 922–927  
 – sequencing 461–481  
 – solid-phase 16, 20–21, 103–125  
 – – automated 118–120, 123  
 – – bi-directional strategy 107  
 – – synthetic strategies 105  
 oligosaccharide-binding proteins 748  
 oligosaccharyl transferase 281–301  
 olivomycin A 690  
 O-mannosyl, brain 754  
 OptiMer 923
- orthogonal  
 – protection 4  
 – reactivities 7  
 orthosomycin 692  
 oxazoline 177
- p**
- PAGE methods 530  
 Pam<sub>3</sub>Cys 394  
 PAP-analogues 789–790  
 PAPs 784, 792  
 – binding site 784  
 – – inhibitors of EST targeted 784–786  
 paromomycin 486, 495–497, 664  
 pathway engineering 156  
 PBPs (penicillin binding proteins) 907  
 PED (pulsed electrochemical detection)  
 501–516  
 – HPACE / PED 502–509  
 PEGA (poly(ethyleneglycol)-polyacrylamide  
 copolymer) 89  
 penicillin binding proteins (PBPs) 907  
 pentane-*syn* interactions 314  
 pentasaccharides, antithrombotic 446–451  
*n*-pentenyl glycoside 9, 118, 265–267  
 PEP (phosphoenol pyruvate) 143, 150  
 peptidoglycan 904–913  
 (Ph<sub>3</sub>P)<sub>3</sub>RhCl / DAB-CO 236  
 1,2-phenylseleno migration 249  
 2-phenylseleno-1-fluoro donor 244  
 2-phenylselenoglycosyl fluoride 234–235,  
 237  
 1,2-phenylsulfero migration 224  
 2-phenylsulfonamido-thioglycoside 26  
 phenylsulfoxide, glycosyl 218  
 phenylthioglycosides 3, 218  
 phosphatidylethanolamine, dipalmitoyl  
 (DPPE) 749  
 phosphites  
 – 2-(diethyl)phosphite 71  
 – diethyl *β*-sialyl phosphites 71  
 – 2-phosphites, as glycosyl donors 71  
 phosphoenol pyruvate (PEP) 143, 150  
 phospholipids, glycosidated 875–881  
 phosphomannose isomerase (PMI) 147  
 O-phosphorylation 664  
*Photobacterium damsela* 86  
 PhSeH 230  
 PhSX-type 75  
 plant phenolics 707  
 plasmon, surface plasmon resonance 132  
 pLDR20-*α*KTUF 158  
 pluramycin 689–690

- PMB (*p*-methoxybenzyl) 110  
 PMI (phosphomannose isomerase) 147  
 PNGase 515  
 poly(ethyleneglycol)-polyacrylamide copolymer (PEGA) 89  
 polyene 697–699  
 polyethyleneglycol (PEG) 11–12, 19  
 – monomethyl ether (MPEG) 11–12  
 polyketide 703–704, 915  
 polymers  
 – high-performance 130  
 – water-soluble 136  
 polymer-supported synthesis of carbohydrates 129–136  
 polyoxin D 625  
 polyphosphate 155  
 polysaccharide (PSA) 363–375  
 – acidic 425–430  
 – extended helical epitope of PSA 364–365  
 – GAG complex polysaccharides 517–521  
 – on human cells 371–373  
 – lipopolysaccharide (LPS) 341, 346–348, 352, 400–401, 815  
 – NPr PSA 370, 373  
 – vaccines, bacterial polysaccharide (*see there*) 397–401, 402–403  
 B-polysaccharide-protein conjugates 363–364  
 polysialic acids 56, 357–375  
 polystyrene (PS) 16, 19  
 – Merrifield-type 19  
 – PS divinylbenzene, cross-linked 16  
 PPA (pyrophosphatase) 145  
 primers, water-soluble 131  
 programmable oligosaccharide synthesis 31  
 – one-pot oligosaccharide synthesis 922–927  
 protease inhibitors (serpins) 416  
 proteoglycans, keratan sulfate 424  
 – cartilage proteoglycans 424  
 – corneal proteoglycans 424  
 PSA (*see* polysaccharide) 363–375  
 PSGL-1 187, 503–504, 805  
 – glycopeptide 187  
 – rPSGL-Ig (*see there*) 503–504, 506, 510–511, 515  
 PTMSEL linker 195  
 pulsed electrochemical detection (*see* PED) 501–516  
 pyridoxal 5'-phosphate (PLP) 718  
 pyrophosphatase (PPA) 145  
 pyrophosphorylase  
 – UDP-Glc 142  
 – UDP-GlcNAc 145
- q**  
 QS-21 204, 384, 391–392
- r**  
 radial topology 572  
 ramnoplanin 697  
 reaction progress, monitoring 26–29  
 regeneration  
 – of CMP-Neu5Ac 149  
 – of GDP-Fuc 148  
 – of GDP-Man 148  
 – of sugar nucleotides 139  
 – of UDP-GlcNAc 145–146  
 retaining glycosyltransferase 636–640  
 Rev-RRE binding 672  
 Rho A 878  
 ring-open metathesis polymerization (ROMP) 578–580, 601, 604  
 RNA  
 – as an emerging therapeutic target 661–663  
 – glycosylated agents that interact with RNA 692–695  
 – heterocyclic 2-deoxystreptamine aminoglycoside analogues, interaction with RNAs 483–498  
 – identifying RNA targets and developing binding assays 670–673  
 – neomycin and TAR RNA 489–490  
 – RNA aptamers 666  
 – RNA major groove 497  
 – RNA polymerase II 201  
 – rRNA (*see there*) 497  
 – single-stranded RNA 662  
 RNA-aminoglycoside 497, 694  
 – aminoglycosides as RNA-binders 666–670  
 – guanidinoglycoside 677–679  
 – interactions 661–680  
 RNA-ligand  
 – A-site 486, 493  
 – binding 486  
 – recognition 661  
 ROESY experiments 332  
 ROMP (ring-open metathesis polymerization) 578–580, 601, 604  
 rPSGL-Ig 503–504, 506, 510–511  
 – N-glycosylation 515  
 rRNA 497  
 – 16S rRNA A-site 497

## s

- saccharomicin 699
- SCLC (small cell lung carcinoma) 391
- selectin ligands
- E-selectin 44, 804, 814–815
  - expression on cancer cells 809–812
  - L-selectin 41, 43–46, 416, 603–604, 807
  - - lymph node infiltration mediated by L-selectin 807
  - - shedding 604
  - multivalent ligands and the selectins 603–604
  - P-selectin 44, 416, 501–516
  - regulation of selectin expression on endothelial cells 814–816
  - sialyl *Lewis* (see *there*) 41, 44–46, 52, 67, 88, 181, 188
- selectin-mediated adhesion 803, 806
- selenium-assisted coupling 232
- 3-seleno auxiliaries 74–77
- 2-seleno-1-fluoro derivat 220
- selenoglycoside 225
- selenyl glycosides 6
- sepsis, lipid A antagonist for sepsis treatment 341–353
- sequencing of oligosaccharides and glycoproteins 461–481
- chromatography (see GC-MS) 462, 471, 527
  - consensus sequence Asn-Xaa-Ser/Thr 282
  - FACE (fluorophore-assisted carbohydrate electrophoresis) 530
  - glycan, sequencing and structural determination 470–475
  - glycomics, mammalian 475–477
  - mass spectrometry (see *there*) 462–466, 471, 533–536
  - - MS-based sequencing strategies 466–470
  - - MS/MS and mass analyzers 465–466
  - NMR spectroscopy 23, 327, 532–533
  - PAGE methods 530
  - special case strategies 477–481
- Shiga*-like toxin
- bundle's decavalent ligand for the *E. coli* *Shiga*-like toxin 582–583
  - P<sup>k</sup>-trisaccharide ligands 557–561
  - radially arranged multivalent ligands for 565–570
- sialic acid 55–94
- C- and S-glycosides 91–94
  - chemical glycosylation 59–83
  - L-sialic acid 903
  - N-acyl-modified sialic acids 869–871
  - polysialic acids 56, 357–375
- sialidase 90–91, 832–834
- sialosides, (2→8)-linked 77–83
- sialyl
- anti-sialyl Le<sup>x</sup> antibody 813
  - diethyl β-sialyl phosphites 71
  - Le<sup>a</sup>/sialyl *Lewis*<sup>a</sup> 803, 816–822, 823
  - - expression in cancer 816, 823–824
  - - sialyl Le<sup>a</sup>/sialyl Le<sup>x</sup>, terminal structures 812
  - Le<sup>x</sup>/sialyl *Lewis*<sup>x</sup> 23, 41, 44–46, 52, 67, 88, 181, 188, 503, 803
  - - anti-sialyl Le<sup>x</sup> antibody 804
  - - enhanced expression of sialyl Le<sup>x</sup> and sialyl Le<sup>a</sup> in malignant cells 816
  - - expression in cancer 816, 823–824
  - - α-O-linked sialyl *Lewis*<sup>x</sup> 188
  - - sialyl Le<sup>a</sup>/sialyl Le<sup>x</sup>, terminal structures 812
  - - 6-sulfo sLe<sup>x</sup> (see *there*) 23, 41, 44–46, 52, 67, 88, 181
  - (2→8)-linked sialyl dimer 73
  - (2→9)-linked derivative 73
  - 2-thiocresol sialyl 68
- sialylation
- DMTST-promoted 63
  - Q-sialylation 60–72
- sialylparagloboside (SPC) 40
- sialyltransferase (SiaT) 84–90, 150, 818–820
- from *Neisseria gonorrhoeae* 86
  - α(2→3)-sialyltransferase 186, 647
  - α(2→6)-sialyltransferase 84, 87, 641–646
  - α(2→8)-sialyltransferase 84, 647
  - SiaT isoenzymes 818–819
- siglec ligands 46–50
- gangliosides (see *there*) 47–49
- silica, amino-bonded 528
- silver silicate (insoluble Ag salt) 261
- silyl ethers 108–109
- single-glycoform proteins 182
- SnCl<sub>2</sub>-mediated coupling 229
- solid-phase synthesis 174
- SPC (sialylparagloboside) 40
- sphingoglycolipid 133
- spiramycin 694
- statistical effect 577
- stereoelectronic effects 306–309
- steric 1,3-diaxial-like interactions 320, 323
- STn(c)-MBS-KLH 386
- streptomycin 694
- sucralfate (carafate®) 429

- sucrose synthase 142
  - sugar
    - branched-chain sugars, biosynthesis of 730–733
    - deoxysugars, biosynthesis of 714–725
    - 2,6-dideoxy-L-sugar 225
    - enzymatic mechanism in the biosynthesis of unusual sugars 713–741
    - GC-MS sugar analysis 571
    - glycosyltransferases / glycotransferase inhibitors
      - – NDP-sugar donors 610–640
      - – NMP-sugar donors 641–648
    - isolation of sugar ring fragments from neomycin 494
    - nucleotides 139
    - – regeneration 139
    - sugar as a new tool for development of therapeutic agents 863–872
  - sugar-1-phosphate thymidyltransferase 917
  - sulfated
    - chitins 427
    - gangliosides 50
    - molecules, fully synthetic 428–430
  - sulfation, biology of 781–783
  - 4-sulfo-GalB30 774
  - 4-sulfo-Gal<sup>18</sup>Cer 774
  - sulfogalactosyl ceramide 772–775
  - 3-sulfogalactosylglycerolipid 772
  - sulfo-Le<sup>a</sup> sequences 753
  - sulfo-Le<sup>x</sup> 23, 41, 44–46, 67, 753
    - 6-sulfo sLe<sup>x</sup> (6-sulfo sialyl Lewis<sup>x</sup>) 23, 41, 44–46, 67, 753, 807, 811–812, 820
    - – 6-sulfo cyclic sLe<sup>x</sup> 45
    - – 6-sulfo de-N-acetyl sLe<sup>x</sup> 46
    - sequences 753
    - synthesis 56–59
  - sulfonated molecules 428
  - sulfonates
    - N-sulfonates 451
    - trifluoromethanesulfonate, dimethyl(methylthio)sulfonium (see DMTST) 62–63
  - sulfotransferases 820–821
    - biology of sulfation 781–783
    - bisubstrate analogue approach to EST inhibition 788–789
    - cancer therapy 820–821
    - discovery of EST inhibitors from a library of PAP analogues 789–790
    - Golgi-resident (GST) 792–794
    - inhibition of EST by dietary agents and environmental toxins 791–792
    - inhibitors of EST targeted toward the PAPS binding site 784–786
    - small molecule inhibitors of 781–796
    - tyrosyl-protein sulfotransferase-1 (TPST-1) 89
  - sulfur-directed glycosidation 224
  - superbeads 154
  - superbug, Wang's 157–160
  - surface plasmon resonance 132, 368
  - swainsonine 300
  - syn-pentane interactions 314
- t**
- T antigen 179, 186, 204
  - T cell 206–209
    - epitopes 383
    - – CD4<sup>+</sup> 396
    - helper T cell 206
    - receptor 207
  - T lymphocytes by ManProp 869
  - T<sub>1</sub> value 28
  - T<sub>4</sub> β-glucosyltransferases 614
  - Tat-TAR 666
  - TDP-[4-<sup>3</sup>H]-6-deoxy-D-glucose 716
  - TDP-2,6-dideoxy-D-glycero-D-galacto-4-hexulose 721
  - TDP-4-keto-6-deoxyglucose 720
  - TDP-D-glucose 4,6-dehydratase 715
  - teicoplanin 909
  - TeNT H<sub>c</sub> 51
  - TentaGel 30, 107
  - TGF-β 809
  - thermodynamic models of multivalency effect 541–573
  - 3-thio auxiliaries 74–77
  - 2-thiocresol sialyl 68
  - thioesters, glycopeptide 199
  - thioglycosides 6, 115–117, 218, 233
    - linkers 110
  - 2-thiophenyl glycosides 67
  - thiosialosides 93
  - D-threo-1-deoxy-1-morpholinoceramide 612
  - thrombin 442
    - inhibition 452–455
    - – domains (see there) 452–454
  - thrombocytopenia, heparin-induced (HIT) 441
  - thromboembolism, venous (VTE) 441
  - thymidyltransferase, sugar-1-phosphate 917
  - TIPSoTf 227, 243
  - TMSOTf 235, 237
  - TNF-α 341, 347, 352
  - TOCSY 532